Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interferon Sparing Strategy of Sofosbuvir Plus Ribavirin for the Treatment of Recently Acquired Hepatitis C Infection

NCT02156570 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.

NCT NCT02156570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02156570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interferon Sparing Strategy of Sofosbuvir Plus Ribavirin for the Treatment of Recently Acquired Hepatitis C Infection
Lead sponsor
Kirby Institute
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2014
Completion date
December 31, 2017
Enrollment
20 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c